In previous studies, individual G9a inhibitor BIX01294 at low concentrations showed a moderate effect on the viability of U87 cells, and a synergistic effect was identified on inhibition of glioma cell viability in combination with G9a, EZH2, and HDAC inhibitors.13 This evidence concerns the gene EZH2 and central nervous system cancer.